CARBATROL (carbamazepine) by Takeda is cytochrome p450 3a4 inducers [moa]. Approved for mood stabilizer [epc]. First approved in 1997.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
CARBATROL is an extended-release oral capsule formulation of carbamazepine, a mood stabilizer and cytochrome P450 3A4 inducer approved in 1997. It is indicated for mood stabilization and works by inducing hepatic metabolism, affecting drug-drug interactions significantly. The extended-release formulation improves dosing convenience and tolerability compared to immediate-release alternatives.
Modest Part D spending signals a niche product facing imminent loss of exclusivity; expect consolidation and transition planning rather than growth opportunities.
Cytochrome P450 3A4 Inducers
Mood Stabilizer
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Verducatib in the Blood
Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults
To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants
Worked on CARBATROL at Takeda? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CARBATROL offers limited career momentum given its LOE-approaching status and modest market footprint (11,966 Part D claims in 2023). Roles are concentrated in defensive commercial activities, risk management, and transition planning rather than growth-oriented innovation, making it a consolidation or stepping-stone position.